Navigation Links
Cardium Announces Retirement of Director

SAN DIEGO, Jan. 26 /PRNewswire-FirstCall/ -- Cardium Therapeutics (NYSE Alternext US: CXM) today reported that Ronald I. Simon (age 70) has retired from the Company's Board of Directors. The resignation reduces the size of Cardium's board to seven directors. "We thank Dr. Simon for his service to the Board and wish him all the best in the years ahead," stated Christopher J. Reinhard, Chairman and Chief Executive Officer of Cardium Therapeutics.


About Cardium

Cardium Therapeutics, Inc. and its subsidiaries, InnerCool Therapies, Inc. and the Tissue Repair Company, are medical technology companies primarily focused on the development, manufacture and sale of innovative therapeutic products and devices for cardiovascular, ischemic and related indications.

Cardium's InnerCool Therapies subsidiary is a San Diego-based medical technology company in the emerging field of temperature modulation therapy to rapidly and controllably cool the body in order to reduce cell death and damage following acute ischemic events such as cardiac arrest or stroke, and to potentially lessen or prevent associated injuries such as adverse neurological outcomes. For more information about Cardium's InnerCool subsidiary and patient temperature modulation, including InnerCool's new RapidBlue(TM) System, which just received FDA clearance, and its CoolBlue(TM) System, please visit

Cardium also has two biologic candidates in clinical development. Cardium's Tissue Repair Company subsidiary (TRC) is focused on the development of growth factor therapeutics for the treatment of severe chronic diabetic wounds. TRC's lead product candidate, Excellarate(TM), is a DNA-activated collagen gel for topical treatment formulated with an adenovector delivery carrier encoding human platelet-derived growth factor-BB (PDGF-BB). Excellarate(TM) is initially being developed to be administered once or twice for the potential treatment of non-healing diabetic foot ulcers. Other potential applications for TRC's Gene Activated Matrix(TM) (GAM) technology include therapeutic angiogenesis (cardiovascular ischemia, peripheral arterial disease) and orthopedic products, including hard tissue (bone) and soft tissue (ligament, tendon, cartilage) repair. For more information about Cardium's Tissue Repair Company subsidiary, please visit

Cardium's Generx product candidate (alferminogene tadenovec, Ad5FGF-4) is a DNA-based growth factor therapeutic being developed for potential use by interventional cardiologists as a one-time treatment to promote and stimulate the growth of collateral circulation in the hearts of patients with ischemic conditions such as recurrent angina. For more information about Cardium Therapeutics and its businesses, products and therapeutic candidates, please visit or view its 2007 Annual Report at

Forward-Looking Statements

Except for statements of historical fact, the matters discussed in this press release are forward looking and reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond our control and may cause actual results to differ materially from stated expectations. For example, there can be no assurance that results observed in one study or using one type of product or procedure will be replicated in subsequent studies or in studies using newly-developed products or procedures, that planned product development efforts and clinical studies can be performed in an efficient and effective manner, that regulatory approvals can be obtained in a timely manner or at all, that partnering, distribution or other commercialization efforts can be achieved and if so that they will effectively accelerate InnerCool's patient temperature modulation business or market, that product modifications or launches will be successful or that the resulting products will be favorably received in the marketplace, that our products or proposed products will prove to be sufficiently safe and effective, that our products or product candidates will not be unfavorably compared to competitive products that may be regarded as safer, more effective, easier to use or less expensive, that results or trends observed in one clinical study will be reproduced in subsequent studies, that third parties on whom we depend will behave as anticipated, or that necessary regulatory approvals will be obtained. Actual results may also differ substantially from those described in or contemplated by this press release due to risks and uncertainties that exist in our operations and business environment, including, without limitation, risks and uncertainties that are inherent in the development, testing and marketing of therapeutic hypothermia devices and the conduct of human clinical trials, including the timing, costs and outcomes of such trials, whether our efforts to launch new devices and systems and expand our markets will be successful or completed within the time frames contemplated, our dependence upon proprietary technology, our ability to obtain necessary funding, regulatory approvals and qualifications, our history of operating losses and accumulated deficits, our reliance on collaborative relationships and critical personnel, and current and future competition, as well as other risks described from time to time in filings we make with the Securities and Exchange Commission. We undertake no obligation to release publicly the results of any revisions to these forward-looking statements to reflect events or circumstances arising after the date hereof.

Copyright 2008 Cardium Therapeutics, Inc. All rights reserved.

For Terms of Use Privacy Policy, please visit

Cardium Therapeutics(TM) and Generx(TM) are trademarks of Cardium Therapeutics, Inc. Tissue Repair(TM), Gene Activated Matrix(TM), GAM(TM) and Excellarate(TM)

are trademarks of Tissue Repair Company.

InnerCool Therapies(R), InnerCool(R), Celsius Control System(R), RapidBlue(TM), CoolBlue(TM), Accutrol(R), Temperature Control Element(R) and TCE(R) and UroCool(TM) are trademarks of InnerCool Therapies, Inc. (other trademarks belong to their respective owners)

SOURCE Cardium Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Cardiums InnerCool Announces First Patient Treated With New Tissue-Specific UroCool(TM) System in Robotic-Assisted Prostate Surgery Study
2. Cardiums InnerCool Announces New Tissue-Specific UroCool(TM) System for Use in Prostate Surgeries
3. Cardium Reports on Third Quarter 2008 Financial Results and Revised Business Strategies for Operating Units
4. Cardium Announces FDA 510(K) Clearance of InnerCools RapidBlue(TM) Endovascular System
5. ITGI Medical Received a CE Mark for its Second Pericardium Covered Stent - AneuGraft(R) - for Tortuous Vessels
6. Cardium Announces InnerCools New RapidBlue(TM) System Obtains CE Mark for Commercial Sale in Europe and UL certification
7. Cardium Announces Follow-On Direct Investment by Institutional Investor
8. Cardium Selected for Inclusion in Russell Microcap Index
9. Cardiums InnerCool Therapies Unit Announces Italian Commercialization Agreement for Portfolio of Temperature Modulation Systems
10. Cardium Launches New AWARE Clinical Study Website
11. Over and Under(R) Pericardium Covered Stent is now in use in England and Proves Great Deliverability
Post Your Comments:
(Date:10/8/2015)... , Oct. 8, 2015  ATCC, the premier global ... it has been selected by The Michael J. Fox ... lines to academic, pharmaceutical, and biotechnology organizations committed to ... the United States , and more than ... the United States , and more than ...
(Date:10/8/2015)... Global Biologics and Biosimilars ... Biosimilars industry . --> Big Market ... Industry 2015 Deep Market Research Report, Size, Share, ... and depth research report on Global Biologics ... , --> ) , ...
(Date:10/8/2015)... 8, 2015 /PRNewswire/ - RepliCel Life Sciences Inc. (OTCQB: REPCF) ... on the development of autologous cell therapies, today announced its ... taking place in the month of October: ... RepliCel will be presenting at the annual Partnering ... Mesa to be held October 7-9 in ...
(Date:10/8/2015)... ... October 08, 2015 , ... ProMIS Neurosciences, ... agreement to develop and commercialize intellectual property rights belonging to The University of ... 2009, and affords exclusive worldwide rights to intellectual property based on use of ...
Breaking Biology Technology:
... , Purpose , ... the use of chloramphenicol (CAP) as a veterinary drug for food ... for the identification and quantification of CAP in milk and milk ... many analytical procedures are described in the literature, the presented method ...
... , ... and detailed structural data of highlyknotted spider toxins , ... The primary structure determination ... cLC 492 sequencing system and the QSTAR Pulsar hybrid quadrupole time-of-flight mass spectrometer. ...
... Abstract , The generation of hybrid ... production is a fundamental and well-established technique. However, , ... , has varied little over the years. ... antigens is particularly problematic. We have developed a robust , ...
Cached Biology Technology:
(Date:10/2/2015)... DUBLIN , Oct. 02 2015 ... addition of the "Enforcing the Law Using ... ) has announced the addition of ... report to their offering. --> Research ... addition of the "Enforcing the Law Using ...
(Date:9/30/2015)... GARDENS, Fla. , Sept. 30, 2015  The ... this month issued another key ruling in favor of ... determination that Korean fingerprint scanner company Suprema and its ... Act of 1930, a trade provision that declares it ... import trade, by infringing two of Crossmatch,s patents, the ...
(Date:9/29/2015)... MILWAUKEE , Sept. 29, 2015  iDAvatars is excited ... partners to introduce its product to market. The official announcement was ... Cognitive Economy event in San Francisco ... Avatar platform powered by IBM Watson. "It is ... the first 100 companies to bring to market the cognitive ...
Breaking Biology News(10 mins):
... 16 issue of the journal Cell Host & ... this immune response in mice infected with lymphocytic choriomeningitis ... of drug treatments for immunosuppressive diseases in humans. ... of the interferon response in vivo," says the paper,s ...
... at the University of Delaware have discovered that when the ... it can send out an S.O.S. to the roots for ... that brings beneficial bacteria to the rescue. The finding ... of passing pathogens--and sheds new light on a sophisticated signaling ...
... TALLAHASSEE, Fla. -- The discovery of a protein involved ... a researcher at the Florida State University College of ... Institutes of Health. Branko Stefanovic, associate professor in ... Medicine, hopes his discovery could lead to treatment methods ...
Cached Biology News: